Centessa Pharmaceuticals Receives FDA Clearance for Phase 1 Clinical Study of ORX142, a Novel Orexin Receptor 2 Agonist

Reuters
16 Jun
Centessa Pharmaceuticals Receives FDA Clearance for Phase 1 Clinical Study of ORX142, a Novel Orexin Receptor 2 Agonist

Centessa Pharmaceuticals plc has announced that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug Application $(IND.AU)$ for ORX142, a novel Orexin Receptor 2 (OX2R) agonist. This clearance allows Centessa to initiate a Phase 1 clinical study of ORX142, aimed at treating select neurological and neurodegenerative disorders. The study will focus on acutely sleep-deprived healthy volunteers to assess the safety, tolerability, and pharmacokinetics of the drug. This approval marks a significant milestone for Centessa, as they explore ORX142's potential to address unmet needs beyond rare hypersomnias. The clinical data from this study is expected later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469225-en) on June 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10